Instrumented measurement of firmness, cohesiveness, adhesiveness, spreadability and springiness for pharmaceutical gels, ointments, creams and pastes — supporting USP <1724>, 21 CFR Part 11 and GMP batch release on the KHT TA-30.
Semi-solid pharmaceutical texture analysis is the instrumented measurement of mechanical and rheological properties — firmness, cohesiveness, adhesiveness, springiness and spreadability — of topical drug products such as gels, ointments, creams and pastes, using a texture analyzer under controlled speed, distance and temperature. In a pharmaceutical QC laboratory, the pharmaceutical gel spreadability test and related semi-solid methods support product development, in-process control, batch release and stability monitoring under USP <1724> Semi-Solid Drug Products — Performance Tests, EP 2.9 general methods and 21 CFR Part 211 GMP requirements.
On the KHT TA-30, a single instrument with interchangeable fixtures covers the full semi-solid toolbox: spreadability rig, back extrusion cell, cone penetrometer and TPA double-compression — from 0.01 N peak force hydrogels to 50 N stiff anhydrous ointments. Unlike a tablet where a single hardness value summarises mechanical behaviour, a pharmaceutical cream or ointment is a multiphase system whose patient-perceived consistency, drug release and clinical acceptability depend on viscoelastic behaviour at shear rates the patient applies with a fingertip.
During formulation development, texture parameters correlate directly with sensorial descriptors that clinical subjects report: firmness with "heaviness", adhesiveness with "stickiness", cohesiveness with "body" or "richness", spreadability with "glide". An anti-fungal cream that is too firm leaves patches un-treated. An ophthalmic gel that is too cohesive will not distribute across the eye. A vaginal gel with insufficient adhesiveness fails its residence time requirement. Every one of these failure modes can be screened on a texture analyzer in minutes, using sample sizes of 20–50 g, long before an expensive clinical or bioequivalence study.
In QC, the texture analyzer provides an objective, number-based check that today's batch behaves like the reference batch. Peak force resolution of 0.01 N, as delivered by the KHT TA-30, catches process drift — a slower homogeniser, a warmer cooling bath, a slightly under-charged wax — at in-process control rather than at batch release. The regulatory environment has also tightened: USP <1724> explicitly recognises instrumented texture analysis as an acceptable performance test for semi-solids, and FDA guidance on topical generic bioequivalence increasingly relies on in-vitro comparators including texture to support Q3 microstructure equivalence.
Semi-solid texture analysis relies on a small, well-defined family of numerical parameters, most extracted directly from the force-time or force-distance curve. A texture analyzer with a single 5 kg load cell and 0.01 N resolution, such as the KHT TA-30, handles the full 0.01 N–50 N window without load cell changes — a meaningful operational advantage over budget instruments that require a dedicated low-force cell for hydrogels and a separate cell for stiff ointments.
| Parameter | Definition | Primary Method | Typical Range (Pharma Semi-Solids) | QC Meaning |
|---|---|---|---|---|
| Firmness (Hardness) | Peak compressive force during TPA or penetration/extrusion | TPA, cone penetrometry, back extrusion | Gels 0.1–3 N; creams 0.5–8 N; ointments 2–50 N | Too firm → poor patient acceptance; too soft → tube defects |
| Cohesiveness | Ratio of positive areas under 2nd and 1st bites (A2/A1) | TPA double-compression | 0.3–0.8 (dimensionless) | Ability of the semi-solid to hold together during application |
| Springiness | Distance recovered between bites / original compression distance | TPA double-compression | 0.4–0.9 | Elastic recovery — relevant to pump re-priming and tube refilling |
| Adhesiveness | Negative area under the curve during probe withdrawal | TPA, adhesiveness test | 0.05–5 N·s | Mucoadhesion, substantivity on skin, stickiness |
| Spreadability (Energy) | Work done to force male cone into female cone filled with product | Ortan spreadability rig (45° or 90° cone) | 1–30 N·mm | Ease of application — correlates with patient compliance |
Four test geometries cover virtually all semi-solid pharmaceutical work. Each produces a distinctive force-distance signature and a distinct slate of derived parameters.
Three layers of regulation frame semi-solid texture analysis in a pharmaceutical laboratory. USP <1724> — Semi-Solid Drug Products — Performance Tests explicitly discusses rheological and texture measurements as supportive characterisation, including apparent viscosity, yield stress and consistency. For topical generic submissions, FDA guidance on establishing Q3 microstructural sameness increasingly expects texture parameters as part of the comparative data package.
21 CFR Part 211 and 21 CFR Part 11 translate into four practical requirements for a texture analyzer running semi-solid release tests: (1) method validation per ICH Q2; (2) instrument qualification through IQ/OQ/PQ; (3) 21 CFR Part 11-compliant software with audit trail, user access control and archival; and (4) SOPs for calibration and preventive maintenance. The KHT TA-30 ships with 21 CFR Part 11-compliant software as standard and the GMP validation package (IQ/OQ/PQ templates) is included in the purchase price — eliminating one of the highest-friction line items in pharmaceutical QC procurement.
Fixture selection is the single most frequent source of method error in semi-solid texture analysis. Temperature is also critical: semi-solid texture is strongly temperature-dependent, with many formulations softening by 15–30% per 5 °C rise. For pharmacopoeial work and bioequivalence studies, conditioning at 25.0 ± 0.5 °C is essential. The KHT TA-30 supports Peltier-controlled platforms for tests at 32 °C (skin simulation) or 37 °C (body temperature).
Each of the four primary semi-solid test methods relies on a specific fixture set. The table below summarises the fixture, force range and typical test parameters used on the KHT TA-30 for routine pharmaceutical semi-solid work.
| Method | Fixture | Typical Speed | Typical Depth / Distance | Force Range | Test Duration |
|---|---|---|---|---|---|
| Spreadability (Ortan) | 90° female + 90° male cone | 3.0 mm/s | 23 mm | 0.1–5 N | 20 s per replicate |
| Back extrusion | 35 or 45 mm disc in 50 mm cell | 1.0 mm/s | 25 mm | 0.5–20 N | 50 s per replicate |
| Cone penetrometry | 45° stainless cone | 0.5–2.0 mm/s (driven) | 10 mm | 0.1–10 N | 20 s per replicate |
| TPA (double-compression) | 25 or 35 mm flat cylindrical probe | 1.0 mm/s | 40–60% of sample height | 0.1–8 N | 60 s per replicate |
The following generic protocol sets up the KHT TA-30 for semi-solid performance testing. Product-specific protocols for gels, ointments and creams are provided on the corresponding detail pages.
Common questions about semi-solid pharmaceutical texture analysis.
Transparent $8,000–$13,000 pricing. Every quote includes the IQ/OQ/PQ validation package, 30+ method library, 21 CFR Part 11 software, standard probe set, and 2-year warranty. Response within 24 hours; engineering SLA within 48 hours.
© 2026 KHT Pharmaceutical Texture Analyzer | pharmaceuticaltextureanalyzer.com